Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS
January 6th 2025A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Functional Precision Medicine Tool Predicts Treatment Response in AML
January 6th 2025A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
Canadian Study Highlights Care Variability for Older Patients With MDS/AML
December 19th 2024A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
Luspatercept Promising Against Anemia in MDS
December 18th 2024Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
New Study Evaluates Quality-of-Life Instruments for Patients With PAH
December 12th 2024A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.
Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis
December 1st 2024Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita
November 8th 2024A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing allogeneic hematopoietic cell transplantation did not negatively affect survival or increase complications.
Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine
November 8th 2024Researchers introduce a telemedicine system powered by artificial intelligence (AI) that automatically scores neuromuscular examinations, offering the potential to enhance patient monitoring, reduce variability in clinical trials, and improve access to care for neuromuscular disorders like myasthenia gravis.
CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications
October 17th 2024A new study reviews how various routes of adeno-associated virus (AAV) gene therapy administration influence local and peripheral immune responses, with a focus on those observed in clinical trials targeting the central nervous system (CNS).
New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+
October 3rd 2024Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.